Best Peptide for Belly Fat: Ranking the Options by Evidence Level

Key takeaways:

• Tesamorelin is the only peptide FDA-approved specifically for visceral fat reduction (in HIV-associated lipodystrophy) with direct imaging data showing visceral fat decrease
• GLP-1 agonists like semaglutide and tirzepatide reduce overall body fat, including visceral fat, with the largest clinical evidence base
• AOD-9604 targets lipolysis through a growth hormone fragment mechanism but has very limited human clinical data
• MOTS-c is a mitochondrial-derived peptide with early-stage research in metabolic function -- not yet studied for belly fat specifically in humans
• "Belly fat" and visceral fat are related but not identical -- visceral fat surrounds organs and is the metabolically dangerous type

Important: This article is for educational and informational purposes only. It is not medical advice. Some compounds discussed are research peptides that are not FDA-approved for weight loss or fat reduction. Always consult a qualified healthcare provider before considering any peptide therapy. See our full medical disclaimer.

Belly fat vs visceral fat: why the distinction matters

When most people say "belly fat," they mean the visible fat around their midsection. But not all abdominal fat is the same.

Subcutaneous fat sits just beneath the skin. You can pinch it. It is the fat that makes your waistband tight. While cosmetically frustrating, subcutaneous fat is not the primary metabolic concern.

Visceral fat surrounds your internal organs -- liver, intestines, pancreas. You cannot pinch it. It is measured by CT scans, MRIs, or DEXA scans. Visceral fat is metabolically active, releasing inflammatory cytokines and hormones that increase risk for type 2 diabetes, cardiovascular disease, and fatty liver disease.

When evaluating peptides for "belly fat," the question with the most clinical relevance is: which peptides have evidence for reducing visceral fat specifically?

Here is what the data says, ranked by evidence strength.

1. Tesamorelin -- the only FDA-approved visceral fat peptide

Tesamorelin (brand name Egrifta) is a growth hormone-releasing hormone (GHRH) analog. It is the only peptide with FDA approval specifically for reducing visceral adipose tissue, though that approval is limited to HIV-associated lipodystrophy -- a condition where antiretroviral medications cause abnormal fat accumulation around the abdomen.

The key study: a randomized, placebo-controlled trial showed that tesamorelin reduced visceral adipose tissue (VAT) by approximately 15% over 26 weeks, as measured by CT imaging (PMID: 20739384). Trunk fat also decreased significantly. Importantly, the visceral fat reduction occurred without significant changes in subcutaneous fat or overall body weight in many participants -- suggesting targeted visceral fat mobilization.

How it works: tesamorelin stimulates the pituitary gland to release natural growth hormone, which in turn drives lipolysis preferentially in visceral fat depots. Unlike injecting exogenous growth hormone directly, tesamorelin preserves the body's natural pulsatile GH release pattern.

Strengths:

• Direct visceral fat reduction data via CT imaging
• FDA-approved (for HIV lipodystrophy)
• Does not suppress the body's own GH production
• Well-studied safety profile in its approved indication

Limitations:

• FDA approval is only for HIV-associated lipodystrophy, not general obesity
• Off-label use for general visceral fat reduction is common but not supported by large trials in non-HIV populations
• Requires daily subcutaneous injection
• Cost: approximately $1,000-1,500/month
• Contraindicated in people with active cancer or pituitary tumors

For general population belly fat reduction, tesamorelin shows the most direct mechanism. But the clinical evidence for non-HIV visceral fat reduction is extrapolated, not proven in large trials.

2. GLP-1 agonists -- the strongest overall evidence

Semaglutide and tirzepatide are not marketed as "belly fat" treatments. But by producing substantial total body fat loss, they reduce visceral fat as part of the overall reduction.

The STEP 1 trial showed semaglutide 2.4mg produced 14.9% average body weight loss over 68 weeks (PMID: 33567185). Body composition substudies have confirmed that a significant portion of the fat lost is visceral. One SURMOUNT substudy using DEXA scans showed that tirzepatide reduced total fat mass by approximately 33.9% while reducing lean mass by approximately 10.9% -- confirming that the majority of weight lost is fat, including visceral depots.

Tirzepatide in the SURMOUNT-1 trial produced 20.9% average weight loss at the 15mg dose over 72 weeks (PMID: 35658024). The dual GLP-1/GIP mechanism appears to produce greater fat loss than GLP-1 alone.

Strengths:

• Massive evidence base (thousands of participants across multiple Phase 3 trials)
• FDA-approved for weight management
• Reduce both visceral and subcutaneous fat
• Metabolic benefits beyond fat loss (improved glycemic control, cardiovascular outcomes for semaglutide)
• Well-characterized side effect profiles

Limitations:

• Not specifically designed for visceral fat -- they reduce total body fat
• Significant GI side effects (nausea, vomiting, diarrhea)
• Lean muscle mass loss is a documented concern
• Cost: $1,000-1,300/month without insurance
• Weight regain upon discontinuation is common

If your goal is overall fat loss including visceral fat, and you want the most evidence-backed pharmaceutical approach, GLP-1 agonists are the strongest option. They just are not specifically targeting belly fat -- they are reducing everything.

3. Retatrutide -- the emerging leader (not yet available)

Retatrutide deserves mention because its triple agonist mechanism (GLP-1 + GIP + glucagon) may specifically enhance visceral fat loss beyond what dual agonists achieve.

The glucagon receptor component is the key differentiator. Glucagon drives hepatic fat oxidation and appears to preferentially mobilize visceral fat stores. In the Phase 2 trial, retatrutide produced 24.2% weight loss at 48 weeks (PMID: 37351564) and showed dramatic reductions in liver fat content -- with a substantial percentage of participants achieving complete normalization of liver fat.

If Phase 3 data confirms these findings and the compound receives FDA approval, retatrutide could become the most effective pharmaceutical option for visceral and liver fat specifically.

Current status: Phase 3 trials ongoing. Not available outside clinical trials.

4. AOD-9604 -- the research peptide option

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 177-191) designed to stimulate lipolysis without the full metabolic effects of growth hormone.

The mechanism is direct fat metabolism. AOD-9604 stimulates the breakdown of triglycerides in fat tissue (lipolysis) and may inhibit the formation of new fat (lipogenesis) (PMID: 11713870). Animal studies showed preferential fat reduction, and the peptide does not appear to affect blood glucose, IGF-1, or other growth parameters.

The reality check: AOD-9604 has not been studied with visceral fat-specific imaging endpoints in any published human trial of significant size. The Phase 2 clinical trial that was conducted did not demonstrate statistically significant weight loss compared to placebo. It is NOT FDA-approved for any indication.

Online discussions frequently describe AOD-9604 as a "belly fat peptide," but this framing is based on mechanism of action theory and anecdotal reports rather than controlled clinical evidence. The enthusiasm exceeds the data.

Strengths:

• Theoretically targets fat metabolism directly
• Does not suppress appetite (some view this as a benefit)
• Lower cost than GLP-1s (~$100-300/month)
• Does not appear to cause the metabolic disruptions of full-length GH

Limitations:

• No FDA approval
• Phase 2 trial did not meet primary endpoint
• No visceral fat-specific imaging data in humans
• Quality control varies dramatically by source
• Regulatory gray area in the US

5. MOTS-c -- early-stage metabolic research

MOTS-c is a mitochondrial-derived peptide that has generated interest in the longevity and metabolic research community. It appears to regulate metabolic homeostasis, improve insulin sensitivity, and enhance mitochondrial function.

Animal studies have shown that MOTS-c can prevent diet-induced obesity, improve glucose tolerance, and enhance fatty acid oxidation. The mechanism is fundamentally different from GLP-1s or growth hormone fragments -- it works at the mitochondrial level, potentially improving the body's baseline metabolic efficiency.

The reality: MOTS-c research in humans is extremely early. There are no large clinical trials evaluating it for fat loss, belly fat reduction, or weight management. It is a fascinating research compound, but recommending it for belly fat based on current evidence would be irresponsible.

People interested in MOTS-c should understand that they are operating well ahead of the clinical evidence.

Ranking summary: evidence level for visceral/belly fat

Peptide	Direct Visceral Fat Evidence	Overall Evidence Level	FDA Approved	Monthly Cost
Tesamorelin	Strong (CT imaging data)	Moderate (HIV population)	Yes (lipodystrophy)	$1,000-1,500
Semaglutide/Tirzepatide	Moderate (substudy data)	Very strong (Phase 3)	Yes (weight management)	$1,000-1,300
Retatrutide	Promising (Phase 2)	Moderate (Phase 2 only)	No (Phase 3 trials)	Not available
AOD-9604	None (no imaging data)	Weak (Phase 2 failed)	No	$100-300
MOTS-c	None	Very weak (animal only)	No	$150-400

The practical answer

If you are focused specifically on reducing visceral belly fat with the strongest evidence:

With a prescription and budget: Talk to your doctor about GLP-1 agonists (semaglutide or tirzepatide). They have by far the most robust clinical data for overall fat reduction including visceral fat. If you have HIV-associated lipodystrophy, tesamorelin has direct approval for that indication.

If GLP-1s are not an option: Tesamorelin used off-label has the most direct mechanistic rationale for visceral fat, but insurance will not cover it for this use and the evidence outside HIV populations is limited.

The foundation regardless of peptides: No peptide replaces the fundamentals. Caloric balance, resistance training, sleep quality, and stress management all independently affect visceral fat accumulation. Any pharmaceutical intervention works best alongside these basics.

For broader context on the weight loss landscape, see our comparison of semaglutide vs tirzepatide and our 2026 pipeline overview.

Sources

1. Falutz J, et al. Effects of tesamorelin on body composition and metabolic parameters in HIV-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010;95(9):4291-304. PMID: 20739384
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
4. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001;142(12):5182-9. PMID: 11713870
5. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526. PMID: 37351564

---

This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. See our full medical disclaimer.